A decade of achievement in pulmonary hypertension

European Respiratory Review

Volumn 20, Issue 122, 2011, Pages 215-217

  Humbert, M ^a,b,c   Simonneau, G ^a,b,c   Rubin, L J ^d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; MACITENTAN; PROSTACYCLIN; PROSTANOID; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL;

CARDIOPULMONARY HEMODYNAMICS; CLINICAL CLASSIFICATION; COMBINATION CHEMOTHERAPY; DETERIORATION; DISEASE ASSOCIATION; DISEASE REGISTRY; DYSPNEA; EDITORIAL; FATIGUE; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; MONOTHERAPY; PATIENT IDENTIFICATION; PROGNOSIS; PULMONARY HYPERTENSION; RISK FACTOR; SURVIVAL RATE; SYNCOPE; TREATMENT RESPONSE; WEAKNESS;

ANTIHYPERTENSIVE AGENTS; BIOMEDICAL RESEARCH; DISEASE MANAGEMENT; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PROGNOSIS; TREATMENT OUTCOME;

EID: 82555195593     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007311     Document Type: Editorial

References (29)

1. Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol 2006; 61: 243-245.
2. Jardim C, Hoette S, Souza R. Contemporary issues in pulmonary hypertension. Eur Respir Rev 2010; 19: 266-271.
3. Hatano S, Strasser T. Primary Pulmonary Hypertension. Geneva, World Health Organization, 1975.
4. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
6. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S78-S84.
7. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
8. Galié N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
9. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev 2010; 19: 314-320.
10. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
11. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; [Epub ahead of print DOI: 10.1002/art.30541].
12. Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011; 20: 270-276.
13. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
14. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
15. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
16. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
17. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
18. McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010; 122: 106-108.
19. O'Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011; 8: 526-538.
20. McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011; 20: 262-269.
21. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
22. Sitbon O, Galiè N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010; 19: 272-278.
23. Gatzoulis MA. The management of Eisenmenger syndrome in the modern treatment era: a case report. Eur Respir Rev 2011; 20: 293-296.
24. Sitbon O, Simonneau G. Optimal management of severe pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 254-261.
25. Humbert M, Montani D, Souza R. Predicting survival in pulmonary arterial hypertension: time to combine markers. Chest 2011; 139: 1263-1264.
26. Howard LS. Prognostic factors in pulmonary arterial hypertension: Assessing the course of the disease. Eur Respir Rev 2011; 20: 236-242.
27. Vonk Noordegraaf A, Galiè N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 243-253.
28. Gupta H, Ghimire G, Naeije R. The value of tools to assess pulmonary arterial hypertension. Eur Respir Rev 2011; 20: 222-235.
29. Hoeper MM. title typecontributor"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation/title. Eur Respir Rev 2011; 20: 297-300.